2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
1
Active Trials
200 recruiting
4
Rare Diseases
across 6 areas
0
News (30d)
Quiet
Afimmune is a company with 2 orphan drug designations across 4 rare diseases. Active clinical trials in 1 indication. gene therapy candidates in 1 disease. 57 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| idiopathic pulmonary fibrosis | 15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester | Des.TrialAppr. |
| sickle cell disease | 15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester (15(S)-HEPE-EE) | Des.TrialAppr. |
| sickle cell-hemoglobin c disease syndrome | 15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester (15(S)-HEPE-EE) | Des.TrialAppr. |
| sickle cell-hemoglobin d disease syndrome | 15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester (15(S)-HEPE-EE) | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
12
overlap in 2+ diseases
1/4
candidate diseases
0
avg importance: 0
57
affecting portfolio
0% of portfolio targets high unmet need diseases
12
overlap in 2+ diseases
1/4
candidate diseases
0
avg importance: 0
57
affecting portfolio